CalciMedica
505 Coast Boulevard South
Suite 209
La Jolla
California
92037
United States
Tel: 858-952-5500
Fax: 858-952-5490
Website: http://www.calcimedica.com/
Email: info@calcimedica.com
62 articles about CalciMedica
-
Clinical Catch-Up: December 14-18
12/21/2020
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look. -
Vir and GSK Dose First Patient in COVID-19 Monoclonal Antibody Study and Other Pandemic Updates
12/18/2020
Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study assessing the monoclonal antibody VIR-7831 as a potential treatment of hospitalized adults diagnosed with COVID-19. -
As we eagerly look ahead to 2021, BioSpace spoke to four biotechs hoping to seize this opportunity in the first wave of COVID-19 vaccines and therapies – or make an impact in the second.
-
CalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia
12/17/2020
CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (“CRAC”) channels for the treatment of severe acute and chronic inflammatory diseases, today announced that the trial evaluating Auxora™ in patients with severe COVID-19 pneumonia has received a recommendation to continue
-
CalciMedica Announces Publication of Preclinical Data Demonstrating the Pathological Role of Microglial CRAC Channels in Ischemic Stroke
11/13/2020
CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced the publication of preclinical data demonstrating a pathological role for CRAC channel-mediated microglial calcium activity in ischemic brain injury in the peer-reviewed journal Stroke.
-
CalciMedica Appoints Daniel Geffken as Interim Chief Financial Officer
11/5/2020
CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced it has appointed Daniel Geffken as the interim chief financial officer.
-
CalciMedica Announces Peer-Reviewed Publication of Positive COVID-19 Data and Initiation of Blinded, Placebo-Controlled Trial of Auxora™ in Patients with Severe COVID-19 Pneumonia
8/18/2020
Study published in Critical Care journal shows patients with severe COVID-19 pneumonia treated with Auxora and standard of care had substantially improved outcomes compared to patients on standard of care alone Clinical trial to enroll up to 400 patients at sites across the U.S., including California, Texas and Louisiana, is being initiated this week
-
CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies
7/21/2020
Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate its drug discovery pipeline LA JOLLA, Calif. and SZEGED, Hungary and BUDAPEST, Hungary, July 21, 2020 (GLOBE NEWSWIRE) -- CalciMedica, a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, and EpiPharma, a
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
-
CalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia
7/16/2020
CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced data from a randomized, controlled, open-label clinical study showing substantially improved outcomes with Auxora™ (formerly called CM4620-IE) as a treatment for severe COVID-19 pneumonia.
-
BioSpace Movers & Shakers, June 5
6/5/2020
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers. -
UPDATE - CalciMedica Appoints Robert N. Wilson as Co-Chairman of the Board of Directors and Eric W. Roberts as Vice Chairman
6/2/2020
CalciMedica Inc. announced the appointment of Robert N. Wilson, a former vice chairman of the Johnson & Johnson board, to the Company’s board of directors as co-chairman with current board chairman, Robert McNeil, Ph.D.
-
CalciMedica Robert N. Wilson, Former J&J Vice Chairman as Co-Chairman of the Board of Directors and Eric W. Roberts as Vice Chairman
6/2/2020
CalciMedica Inc., a clinical-stage biotechnology company targeting calcium release-activated calcium channels for the treatment of acute and severe inflammatory diseases including acute viral pneumonia in COVID-19 patients, announced the appointment of Robert N. Wilson, a former vice chairman of the Johnson & Johnson board, to the Company’s board of directors as co-chairman with current board chairman, Robert McNeil, Ph.D.
-
Clinical Catch-Up: May 25-29
6/1/2020
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look. -
CalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia
5/28/2020
Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
-
CalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences
5/22/2020
CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced it has raised $15 million in a Series C financing round. The round was led by Valence Life Sciences, L
-
CalciMedica Announces that FDA Has Strongly Recommended Moving to a Blinded Placebo-controlled Trial with Auxora™ in Patients with Severe COVID-19 Pneumonia
5/21/2020
CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced that it has received guidance from the U.S. Food and Drug Administration (FDA) regarding the Company’s ongoing study of Auxora™ (formerly called CM4620-IE) in patients with COVID-19 pneumonia. The FDA has strongly recomme
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.
-
Clinical Catch-Up: May 4-8
5/11/2020
It’s the first time in several weeks that the number of non-COVID-19-related clinical trial stories outnumber the COVID-19-related stories. It’s also a hopeful sign that some of the rest of the clinical trials are getting back on track. Here’s a look.